{"groups":[{"description":"200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.","id":"FG000","title":"Multi-kinase Inhibitor Fosamatinib Disodium"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}